Description of Operations and Summary of Significant Accounting Policies (Details) (USD $)	0 Months Ended					6 Months Ended
	Jun. 02, 2014	Jun. 01, 2014	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014 Theravance Biopharma Common stock	Jun. 30, 2014 GSK LABA collaboration and Strategic Alliance agreements
Description of operations
Percentage of economic interest in any future payments made under the agreements						15.00%
Business Separation
Cash, cash equivalents and marketable securities contributed to Theravance Biopharma		$ 393,000,000
Number of ordinary shares of Theravance Biopharma issued for every share of Theravance	0.286
Number of ordinary shares owned as available-for-sale securities					436,802
Inventories
Raw materials			0	5,138,000
Work-in-process			0	360,000
Finished goods			0	4,908,000
Total inventories			$ 0	$ 10,406,000